HUTCHMED (China) Limited (AIM:HCM)

Market Cap	1.77B -12.6%
Revenue (ttm)	407.54M -13.0%
Net Income	339.48M +1,111.0%
EPS	0.39 +1,200.0%
Shares Out	859.74M
PE Ratio	5.33
Forward PE	25.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,009
Average Volume	20,518
Open	207.40
Previous Close	206.00
Day's Range	197.55 - 213.00
52-Week Range	185.50 - 292.00
Beta	0.51
RSI	39.10
Earnings Date	Mar 5, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,796
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HCM

Financial Performance

In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.

Financial numbers in USD